Table 1.
Demographic, clinical, and virologic characteristics of the cohort, overall and stratified by ever having HHV-6 reactivation at any level, HHV-6 >median maximum (785 copies/mL), or delirium after CBT
| Characteristic† | Overall, no. (%)(N = 44) | HHV-6 reactivation, no. (%) (n = 44)
|
Delirium episode, no. (%) (n=35)*
|
|||
|---|---|---|---|---|---|---|
| Any level‡ (n = 29) | HHV-6 > median max (n = 22) | None (n = 15) | Yes (n = 9) | No (n = 26) | ||
| Age, y, median (IQR) | 35 (12–53) | 30 (12–45) | 33 (13–45) | 42 (2–6) | 38 (30–66) | 42 (23–59) |
| Female sex | 22 (50) | 15 (52) | 13 (59) | 7 (47) | 4 (44) | 15 (58) |
| Caucasian | 28 (64) | 19 (66) | 14 (64) | 9 (60) | 6 (67) | 17 (65) |
| Recipient CMV seropositive | 32 (73) | 24 (83) | 17 (77) | 8 (53) | 8 (89) | 18 (69) |
| High medical comorbidity | 19 (43) | 10 (34) | 8 (36) | 9 (60) | 7 (78) | 11 (42) |
| TBI dose ≥1200 cGY | 22 (50) | 15 (52) | 11 (50) | 7 (47) | 5 (56) | 12 (46) |
| More advanced underlying disease | 27 (61) | 16 (55) | 12 (55) | 11 (73) | 5 (56) | 16 (62) |
| Myeloablative conditioning regimen | 26 (59) | 19 (66) | 14 (64) | 7 (47) | 6 (67) | 12 (46) |
| Double unit CBT | 33 (75) | 23 (79) | 19 (86) | 10 (67) | 9 (100) | 23 (88) |
| HLA 4/6 Mismatch | 23 (52) | 16 (55) | 11 (50) | 7 (47) | 6 (67) | 15 (58) |
| Intensive antiviral prophylaxis | 17 (39) | 12 (41) | 6 (27) | 5 (33) | 5 (56) | 10 (38) |
| Acute GVHD, grade 3–4 | 12 (27) | 7 (24) | 7 (32) | 5 (33) | 3 (33) | 5 (19) |
| HHV-6 reactivation, any | -- | -- | -- | -- | 6 (67) | 18 (69) |
| HHV-6 reactivation >median max | -- | -- | -- | -- | 5 (56) | 13 (50) |
| HHV-6 DNA median max copies/mL (IQR) | 785 (0–6,154) | -- | -- | -- | 3,275 (0–17,224) | 1,074 (0–5,900) |
| HHV-6 day of first detection, (IQR) | -- | 20 (17–28) | 24 (19–27) | -- | -- | -- |
IQR indicates interquartile range; CMV, cytomegalovirus; TBI, total body irradiation; CBT, cord blood transplantation; HLA, human leukocyte antigen; GVHD, graft-versus-host-disease.
*
Nine patients were too young, too sick, or otherwise unable to participate in delirium assessments.
†
Characteristics were defined as previously described (Zerr et al, 2011).
‡
This category includes patients in the HHV-6 >median maximum category.